Johnson & Johnson engages in the research and development, manufacture, and sale of a range of products in the healthcare field.
The company operates through three business segments, including Consumer; Pharmaceutical and Medical Devices; and Diagnostics.
The Consumer segment includes a range of products used in the baby care, skin care, oral care, wound care and women's health care fields, as well as nutritional and over-the-counter pharmaceutical products. The Baby Care franchise includes the JOHNSON'S Baby line of products. Major brands in the Skin Care franchise include the AVEENO; CLEAN & CLEAR; JOHNSON'S Adult; NEUTROGENA; RoC; LUBRIDERM; Beijing Dabao Cosmetics Co., Ltd.; and Vendome product lines. The Oral Care franchise includes the LISTERINE and REACH oral care lines of products. Major brands in the Women's Health franchise are the CAREFREE Pantiliners and STAYFREE sanitary protection products. The nutritional and over-the-counter lines include SPLENDA, No Calorie Sweetener; the family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; ZYRTEC allergy products; MOTRIN IB ibuprofen products; and PEPCID AC Acid Controller from Johnson & Johnson Merck Consumer Pharmaceuticals Co. These products are marketed principally to the general public and sold both to wholesalers and directly to independent and chain retail outlets throughout the world.
The Pharmaceutical segment includes products in the following therapeutic areas: anti-infective, antipsychotic, cardiovascular, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, urology and virology. These products are distributed directly to retailers, wholesalers and health care professionals for prescription use by the general public. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a biologic approved for the treatment of Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis, and use in the treatment of rheumatoid arthritis; TOPAMAX (topiramate), approved for adjunctive and monotherapy use in epilepsy, as well as for the prophylactic treatment of migraines; PROCRIT (Epoetin alfa, sold outside the U.S. as EPREX), a biotechnology-derived product that stimulates red blood cell production; RISPERDAL oral (risperidone), a medication that treats the symptoms of schizophrenia, bipolar mania and irritability associated with autistic behavior in indicated patients, RISPERDAL CONSTA (risperidone), a long-acting injectable, and INVEGA (paliperdone) Extended-Release tablets, for the treatment of schizophrenia; LEVAQUIN (levofloxacin) and FLOXIN (ofloxacin), both in the anti-infective field; CONCERTA (methylphenidate HCl), a product for the treatment of attention deficit hyperactivity disorder; ACIPHEX/PARIET, a proton pump inhibitor co-marketed with Eisai Inc.; and DURAGESIC/Fentanyl Transdermal (fentanyl transdermal system, sold outside the U.S. as DUROGESIC), a treatment for chronic pain that offers a novel delivery system.
Medical Devices and Diagnostics
The Medical Devices and Diagnostics segment includes a range of products distributed to wholesalers, hospitals and retailers, used principally in the professional fields by physicians, nurses, therapists, hospitals, diagnostic laboratories and clinics. These products include Cordis' circulatory disease management products; DePuy's orthopaedic joint reconstruction, spinal care and sports medicine products; Ethicon's surgical care and women's health products; Ethicon Endo-Surgery's minimally invasive surgical products; LifeScan's blood glucose monitoring and insulin delivery products; Ortho-Clinical Diagnostics' professional diagnostic products and Vistakon's disposable contact lenses.
Johnson & Johnson was founded in 1886.
|Jun 2, 2016||Vogue International||$3.3B in Cash|
|Nov 8, 2015||Novira Therapeutics||Unknown|
|Sep 26, 2015||NeoStrata Company, Inc.||Unknown|
|Mar 20, 2015||X01||Unknown|
|Sep 30, 2014||Alios BioPharma||$1.75B in Cash|
|Jun 14, 2014||Synthes||Unknown|
|Jun 17, 2013||Aragon Pharmaceuticals||$1B (terms undisclosed)|
|Jul 19, 2012||Calibra Medical||Unknown|
|Feb 22, 2011||Crucell||$2.3B in Cash|
|Sep 27, 2010||Micrus Endovascular Corporation||Unknown|
|Jul, 2016||Ci:z Holdings||undisclosed amount / Undisclosed||—|
|Apr, 2015||Inter-Grosshandel GmbH||undisclosed amount / Non Equity Assistance||—|
|Sep, 2009||Crucell||$443M / Undisclosed (Lead)||—|
|Jan, 2007||InnerPulse||$50M / Venture (Lead)||—|
|Nov, 2006||CardioMEMS||$22.6M / Series D||—|
|Dec, 2002||Topspin Medical||$16.5M / Series B||—|
Current Team (58)Update
Chairman & CEO
Vice President, Finance and Chief Financial Officer
Vice President, Global Human Resources
Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals Group
Vice President, General Counsel
Company Group Chairman
America’s #1 bandage brand covers all your wound-protection needs. BAND-AID® Brand Adhesive Bandages have covered and protected cuts and
Benadryl (diphenhydramine) is a brand name antihistamine (allergy medicine) marketed over-the-counter by Johnson & Johnson subsidiary
Clean & Clear is a line of dermatology products owned by Johnson & Johnson.
An energizing citrus cleanser helps wake you up and leaves you ready to face the day.
Listerine is a brand of antiseptic mouthwash product. Fight plaque, gingivitis and bad-breath germs with powerful LISTERINE® Antiseptic
Listerine mouthwash range in the middle east provides a complete oral care and hygiene for fresh breath, teeth whitening and cleaner mouth.
Neutrogena the #1 Dermatologist Recommended skincare brand offers a wide range of skin and hair care products.
Neutrogena® ME is the number 1 dermatologist recommended skin care brand in the Middle East.
Sub Organizations (19)Update
|Sep 16, 2016||jnj.com - Johnson & Johnson Announces Agreement To Acquire Alios BioPharma|
|Sep 16, 2016||jnj.com - Johnson & Johnson Announces Completion Of Alios Biopharma Acquisition|
|Sep 14, 2016||jnj.com - Johnson & Johnson Completes Acquisition Of Aragon Pharmaceuticals, Inc.|
|Sep 7, 2016||jnj.com - Johnson & Johnson Announces Completion Of Novira Therapeutics, Inc. Acquisition|
|Aug 6, 2016||google.com - Aug 6, 2016|
|Jun 21, 2016||stratechery by Ben Thompson - TV Advertising’s Surprising Strength — And Inevitable Fall|
|Jun 20, 2016||AdWeek - The Inside Story on J&J's Revamped Marketing Mission Under Alison Lewis|
|Jun 2, 2016||PRNewswire All - Johnson & Johnson Announces Agreement to Acquire Vogue International|
One Johnson & Johnson Plaza
New Brunswick, NJ 08933